A detailed history of E Fund Management Co., Ltd. transactions in Exelixis, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 19,512 shares of EXEL stock, worth $431,215. This represents 0.03% of its overall portfolio holdings.

Number of Shares
19,512
Previous 21,832 10.63%
Holding current value
$431,215
Previous $523,000 11.47%
% of portfolio
0.03%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$20.17 - $23.93 $46,794 - $55,517
-2,320 Reduced 10.63%
19,512 $463,000
Q4 2023

Feb 06, 2024

BUY
$19.25 - $24.13 $22,137 - $27,749
1,150 Added 5.56%
21,832 $523,000
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $49,142 - $58,691
-2,581 Reduced 11.09%
20,682 $452,000
Q2 2023

Aug 11, 2023

BUY
$18.17 - $20.48 $1,998 - $2,252
110 Added 0.48%
23,263 $445,000
Q1 2023

May 11, 2023

SELL
$16.3 - $19.41 $59,495 - $70,846
-3,650 Reduced 13.62%
23,153 $449,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $2,872 - $3,338
192 Added 0.72%
26,803 $430,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $38,776 - $55,073
2,473 Added 10.25%
26,611 $417,000
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $198,083 - $263,051
11,358 Added 88.87%
24,138 $503,000
Q1 2022

May 12, 2022

BUY
$17.03 - $22.67 $41,144 - $54,770
2,416 Added 23.31%
12,780 $290,000
Q4 2021

Feb 11, 2022

BUY
$15.84 - $21.88 $69,822 - $96,447
4,408 Added 74.01%
10,364 $189,000
Q1 2021

May 12, 2021

BUY
$20.53 - $25.22 $122,276 - $150,210
5,956 New
5,956 $134,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.11B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.